Exane Derivatives Decreases Stake in Bristol-Myers Squibb Co (BMY)

Exane Derivatives lessened its position in Bristol-Myers Squibb Co (NYSE:BMY) by 58.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,727 shares of the biopharmaceutical company’s stock after selling 6,517 shares during the quarter. Exane Derivatives’ holdings in Bristol-Myers Squibb were worth $293,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CSat Investment Advisory L.P. purchased a new position in Bristol-Myers Squibb during the second quarter worth approximately $113,000. Landaas & Co. WI ADV purchased a new position in Bristol-Myers Squibb during the second quarter worth approximately $131,000. Mount Yale Investment Advisors LLC purchased a new position in Bristol-Myers Squibb during the first quarter worth approximately $179,000. Selective Wealth Management purchased a new position in Bristol-Myers Squibb during the third quarter worth approximately $184,000. Finally, LFA Lugano Financial Advisors SA lifted its position in Bristol-Myers Squibb by 85.8% during the third quarter. LFA Lugano Financial Advisors SA now owns 3,207 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 1,481 shares in the last quarter. Institutional investors and hedge funds own 72.38% of the company’s stock.

NYSE:BMY opened at $50.43 on Friday. Bristol-Myers Squibb Co has a 52 week low of $46.94 and a 52 week high of $70.05. The company has a current ratio of 1.40, a quick ratio of 1.28 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $80.44 billion, a price-to-earnings ratio of 13.23, a price-to-earnings-growth ratio of 1.50 and a beta of 0.98.



Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 49.20% and a net margin of 6.50%. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. On average, research analysts predict that Bristol-Myers Squibb Co will post 3.85 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Friday, October 5th will be given a $0.40 dividend. The ex-dividend date is Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a yield of 3.17%. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.

BMY has been the topic of a number of analyst reports. Barclays lifted their price objective on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Friday, October 12th. Credit Suisse Group set a $61.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, October 14th. Zacks Investment Research upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price objective on the stock in a research report on Friday, October 5th. ValuEngine downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Finally, Jefferies Financial Group set a $58.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Sunday, July 15th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $62.29.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

See Also: Closed-End Mutual Funds

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply